CRO Partner Growth OpenClinica launched its CRO Partner Program with Endpoint Strategy in January 2026, signaling a strengthened channel strategy targeting CROs and mid-size sponsors. This enables partner-driven deal flow and potential co-sell or resell arrangements to expand reach. The combination of recruitment capabilities from BuildClinical and EDC flow offers a compelling end-to-end value proposition for faster trial timelines. Target CROs and mid-market sponsors with messaging around accelerated enrollment and streamlined data capture.

Credibility Advantage Industry recognition as a Major Contender in the 2024 EDC PEAK Matrix and as a top Contender in Everest Group reinforces OpenClinica's credibility in ease of use, integration, and partnerships. Use these accolades to shorten due diligence cycles with risk-averse buyers in biotech, pharma, academia, and government. Position OpenClinica as a trusted, scalable eClinical platform for regulated trials, with proven interoperability. Leverage the credibility in outreach and case studies.

Enrollment Acceleration The 2025 acquisition of BuildClinical adds patient recruitment capabilities, directly addressing a common bottleneck in clinical research. This enables OpenClinica to offer end-to-end trial acceleration from recruitment through data capture to analytics. The bundled offering is especially attractive to sponsors facing enrollment delays and to mid-market CROs seeking faster study timelines. Consider targeting prospects with messaging around enrollment speed and integrated data workflows.

GTM Refresh OpenClinica appointed Andy Ferrin as Chief Commercial Officer in January 2026, signaling a refreshed go-to-market strategy and stronger enterprise sales focus. This presents an opportunity to pursue larger mid-market and small enterprise accounts and to cross-sell across the expanded platform. Emphasize leadership momentum when engaging with IT, clinical operations, and procurement stakeholders. Prepare targeted plays around sponsorships, CRO partnerships, and end-to-end trial solutions.

Regulated Scale With more than 10,000 studies and over five million patients across pharma, academia, and government, OpenClinica demonstrates broad scale and regulatory readiness. The platform’s HIPAA-aligned security posture and protections such as Cloudflare Bot Management help reassure risk-averse buyers. This breadth supports cross-selling to IT and clinical operations teams seeking scalable, compliant eClinical workflows. Use case examples from these segments can fuel tailored messaging.